Precigen (PGEN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 Jun, 2026Opening remarks and agenda
Meeting called to order by the chairman, with board members and executive leadership introduced.
Virtual meeting procedures and technical support information provided to attendees.
Inspector of Election and independent auditor representatives present for proceedings.
Confirmation of proper notice and availability of annual report and proxy statement.
Board and executive committee updates
Nine nominees for the board of directors presented for election to serve one-year terms.
Shareholder proposals
Four proposals presented: election of directors, ratification of auditor, advisory vote on executive compensation, and amendment to the 2023 Omnibus Incentive Plan.
No questions or comments received from shareholders on any proposal.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Precigen
- Q2 2026 profitability reached as PAPZIMEOS revenue soared to $53.1M and adoption accelerated.PGEN
Q2 2026 - Rapidly approved gene therapy for RRP sees strong uptake and expansion into new markets.PGEN
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - PAPZIMEOS launch drove $21.6M Q1 revenue, rapid adoption, and a sharply narrowed net loss.PGEN
Q1 2026 - Shareholders will vote on director elections, auditor ratification, executive pay, and a key equity plan amendment.PGEN
Proxy filing - Virtual meeting to vote on directors, auditor, compensation, and incentive plan amendment.PGEN
Proxy filing - PAPZIMEOS sets a new standard for RRP, fueling growth and pipeline expansion via a unique platform.PGEN
Fireside chat - PAPZIMEOS launch accelerates revenue growth and adoption, with Q1 2026 revenue set to exceed $18M.PGEN
Q4 2025 - PRGN-2012 pivotal data and cost cuts drive focus as net loss widens and FDA submission nears.PGEN
Q2 2024 - 51% complete response and 86% surgery reduction achieved, with durable efficacy and strong safety.PGEN
Study Result